SCHEMBL4899486

SCHEMBL4899486

CN1CCN(C(=O)c2cc(Cl)c(OCc3ccccc3)c(Cl)c2)c2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 6/20 0.48
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 3/20 0.46
CYP3A4 P08684 3/20 0.46
CYP2D6 P10635 3/20 0.46
CYP2C9 P11712 3/20 0.46
CYP2C19 P33261 3/20 0.46
GLRA1 P23415 2/20 0.42
KCNH2 Q12809 1/20 0.41
NAAA Q02083 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
BRD4 O60885 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
SLC22A12 Q96S37 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4895551 0.90 BRD4 (0.52) KDM4EGLRA1NAAALMNAHPGD
SCHEMBL4900278 0.85 KDM4E (0.43) KDM4EGLRA1NAAALMNAHPGD
SCHEMBL4898058 0.81 AVPR1A (0.44) GPBAR1KDM4EGLRA1NAAABRD4
SCHEMBL4895457 0.81 LMNA (0.56) LMNAHPGDNPC1RAB9AL3MBTL1
SCHEMBL4893108 0.81 POLB (0.58) GPBAR1KDM4ENAAALMNARAB9A
SCHEMBL4900137 0.81 GAA (0.47) GPBAR1KDM4ELMNAHPGDL3MBTL1
SCHEMBL4895480 0.81 AVPR2 (0.58) LMNAHPGDSLC22A12
SCHEMBL4898984 0.80 SLC22A12 (0.52) KDM4ECYP2C9GLRA1NAAASLC22A12
SCHEMBL4903897 0.80 SLC22A12 (0.55) GPBAR1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4901495 0.79 POLB (0.50) GPBAR1KDM4ENAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds JAPAN TOBACCO INC. (JP) 2008-12-11 US disclosed
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds JAPAN TOBACCO INC. (JP) 2008-03-13 US disclosed
EP-1820515-A1 NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF Japan Tobacco, Inc. (JP) 2007-08-22 EP disclosed
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof JAPAN TOBACCO INC. (JP) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds NOD1, NLRP3, SLC10A1 GPBAR1 297/4885KDM4E 2953/4885CYP1A2 229/4885
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof NUDT1, NOD1, SLC28A1 GPBAR1 267/4885KDM4E 3266/4885CYP1A2 914/4885
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds NOD1, XDH, URB2 GPBAR1 1605/4885KDM4E 2773/4885CYP1A2 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.